Full text is available at the source.
Nirmatrelvir/ritonavir may lower long COVID risk in people with weak immune systems
Updated
Abstract
Essence
Acute nirmatrelvir/ritonavir use was associated with lower long COVID risk in immunodeficient patients.
Evidence
A retrospective study examined post-acute sequelae of SARS-CoV-2 infection after acute nirmatrelvir/ritonavir use in immunodeficient patients.
Caveat
The abstract provides no sample size or effect estimate, and the retrospective design leaves the finding in need of clinical trial confirmation.
Simplified
Long Covid